The ability of PAM50 risk of recurrence score to predict 10-year distant recurrence in hormone receptor-positive postmenopausal women with special histological subtypes.

CONCLUSION: In the present study, we demonstrated that Prosigna-PAM50 continuous ROR score added significant prognostic information for 10-year DR in postmenopausal patients with special subtypes (tumor size >20 mm or 1 to 3 positive lymph nodes) and ER-positive, HER2-normal early breast cancer. PMID: 29202609 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/29202609?dopt=Abstract

Source: Acta Oncologica - December 4, 2017 Category: Cancer & Oncology Authors: Laenkholm AV, Jensen MB, Eriksen JO, Buckingham W, Ferree S, Nielsen TO, Ejlertsen B Tags: Acta Oncol Source Type: research